icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Na´ve and Treatment-Experienced Patients With HCV Genotype 2 Infection
 
 
  Reported by Jules Levin
AASLD
66th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco, CA
17 November 2015
 
David Wyles,1 Mark Sulkowski,2 Stanley Wang,3 Michael Bennett,4 Hugo E. Vargas,5 J. Scott Overcash,6 Benedict Maliakkal,7 Asma Siddique,8 Bal Raj Bhandari,9 Fred Poordad,10 Sandra S. Lovell,3 Chih-Wei Lin,3 Teresa I. Ng,3 Federico J. Mensa,3 Jens Kort3
 
1University of California San Diego, La Jolla, CA, USA; 2Johns Hopkins University School of Medicine, Baltimore, MD, USA; 3AbbVie Inc., North Chicago, IL, USA; 4San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, CA, USA; 5Mayo Clinic, Phoenix, AZ, USA; 6eStudySite, San Diego, CA, USA; 7University of Rochester Medical Center, Rochester, NY, USA; 8Virginia Mason Hospital and Medical Center, Seattle, WA, USA; 9Gastroenterology & Nutritional Medical Services, Bastrop, LA, USA; 10Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif